Enzychem Lifesciences Balance Sheet Health
Financial Health criteria checks 6/6
Enzychem Lifesciences has a total shareholder equity of ₩194.6B and total debt of ₩4.4B, which brings its debt-to-equity ratio to 2.3%. Its total assets and total liabilities are ₩211.5B and ₩16.9B respectively.
Key information
2.3%
Debt to equity ratio
₩4.42b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩137.35b |
| Equity | ₩194.63b |
| Total liabilities | ₩16.92b |
| Total assets | ₩211.55b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A183490's short term assets (₩174.5B) exceed its short term liabilities (₩14.2B).
Long Term Liabilities: A183490's short term assets (₩174.5B) exceed its long term liabilities (₩2.8B).
Debt to Equity History and Analysis
Debt Level: A183490 has more cash than its total debt.
Reducing Debt: A183490's debt to equity ratio has reduced from 6.6% to 2.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A183490 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: A183490 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.1% each year